Crotamiton 10%

Quick links

Choose a section

Quick links to important sections

Advertisements

Crotamiton 10%

Selected form

Advertisements

Overview of Crotamiton 10%

Crotamiton 10%: Definition and Pharmacological Classification

Crotamiton 10% is a topical pharmaceutical preparation containing the synthetic organic compound Crotamiton as its sole active ingredient. It is chemically derived from the anilide and benzene derivative families, classifying it as a small molecule synthetic agent. This preparation is recognized as belonging to the pharmacological class of scabicides and antipruritics.

The preparation's primary characteristic is its dual-action capability. It is categorized as both a scabicide and an antipruritic because it is designed to target specific skin infestations caused by mites while simultaneously providing relief from associated itching. This combination offers a comprehensive approach to managing both the parasitic cause and the resulting physical discomfort.

Form, Composition, and Origin

Crotamiton 10% is formulated for exclusive cutaneous application, commonly available in emulsified forms such as a cream or lotion. The fixed 10% concentration of the active substance, Crotamiton, is suspended within an appropriate inactive base. Unlike plant-derived pharmaceuticals, Crotamiton is a synthetic organic compound, produced via chemical synthesis to ensure consistent purity and stability.

This medication is generally positioned for use in adults and older children. As a single-active-ingredient product, its therapeutic effects are derived from the chemical properties of the Crotamiton molecule itself.

General Purpose and Dual Benefit

The primary purpose of Crotamiton 10% is to provide symptomatic relief from intense itching while concurrently addressing the parasitic cause of certain skin infestations. Pharmacological profiles indicate that Crotamiton acts as an acaricide, which targets and eliminates specific parasitic organisms. The antipruritic effect functions by addressing the itching sensation at the skin level, offering symptomatic comfort. This dual action is intended to provide both a resolution to the infestation and relief from the primary symptom.

Regulatory References

  1. Crotamiton Drug Information (DailyMed/NIH)
Advertisements

What side effects are possible with Crotamiton 10%?

Possible Side Effects and Safety Information

The officially documented safety profile for Crotamiton 10% primarily addresses reactions affecting the Skin and subcutaneous tissue disorders. These effects are generally localized to the application site, reflecting the product's topical use. The most commonly noted adverse reactions in regulatory documents include localized primary irritation reactions, rash, dermatitis, and an increase in or worsening of pruritus (itching).


Regulatory Classification of Reactions

Adverse reactions are classified by frequency in regulatory summaries. Effects such as the worsening of pruritus may be listed as uncommon (affecting less than 1 in 100 users). The potential for allergic sensitivity reactions (hypersensitivity), including more severe reactions like angioedema, is recognized and generally categorized as rare. Other irritation responses may be listed with a Not Known frequency, meaning the exact rate cannot be reliably estimated from available data.


Safety Restrictions and Special Populations

Official labeling defines specific restrictions for use. Crotamiton 10% is contraindicated in individuals with known hypersensitivity to the active ingredient or any excipients. Application is restricted on skin that is acutely inflamed, raw, weeping, or affected by acutely exudative dermatoses. Furthermore, the product is not to be applied near the eyes or mouth due to the risk of irritation.

Specific safety considerations exist for pediatric use; application in infants is generally restricted to use under medical supervision. For pregnant individuals, the product is classified as Pregnancy Category C by the FDA, and some international labels recommend avoiding its use during pregnancy.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Crotamiton 10% overdose centers primarily on the outcomes of accidental oral ingestion. Documented manifestations include signs of gastrointestinal distress such as nausea, vomiting, and abdominal pain, along with a burning sensation affecting the oral and digestive mucosa. The systemic risks following ingestion or excessive cutaneous absorption involve the potential for methaemoglobinaemia and, in rare instances reported in regulatory documents, severe Central Nervous System (CNS) effects, including seizure and loss of consciousness.

When to Seek Help

The official labeling explicitly mandates that accidental oral ingestion requires immediately contacting a Poison Control Center. Furthermore, immediate medical attention must be sought for serious symptoms, particularly if an individual experiences trouble breathing or is passing out.

Management strategies described in regulatory texts involve general measures to reduce drug absorption and eliminate the substance, coupled with symptomatic and supportive treatment. For the specific complication of severe methaemoglobinaemia, methylene blue may be considered as a targeted intervention. Regulatory documents note a constraint that specific information on the effects of repeated topical overtreatment in humans is limited.

Advertisements

Therapeutic Uses of Crotamiton 10%

Crotamiton 10% is primarily used within infectious dermatology for its two-fold therapeutic effect, which addresses both the underlying cause of certain skin issues and the resulting intense discomfort. This dual benefit is central to its therapeutic value, and is recognized for its use in contexts involving symptomatic relief.

Key Therapeutic Uses

The medication is commonly used to help with managing scabies, a condition caused by the Sarcoptes scabiei mite, and for providing relief in conditions presenting with intense pruritus (severe itching). Its use may assist with addressing the parasitic cause, and it is relevant across symptom-driven clinical presentations where severe or relentless itching is the primary, distressing manifestation.

It is also applied in contexts where short-term symptomatic assistance is needed for other pruritic skin conditions or to manage post-treatment residual discomfort. This contributes to improved comfort during periods of heightened symptoms and may assist with maintaining a sense of stability.

Quick Fact: Relief for Intense Pruritus Crotamiton 10% is commonly used to help manage the symptom of severe itching associated with certain skin conditions.

Regulatory References

  1. NIH DailyMed Drug Label
Advertisements

Eligibility and Restrictions for Use

Eligibility for Crotamiton 10% Use

Official regulatory guidelines define specific populations who can and cannot use Crotamiton 10%. The medicine is generally permitted for use by Adults and Older Adults. However, several contraindications and restrictions apply based on age, physiological status, and local skin condition.


Absolute Contraindications

Use is strictly prohibited for individuals with a known hypersensitivity or allergy to crotamiton or any components of the formulation. It must also not be used by patients with acute exudative dermatoses (weeping skin conditions) or those who show a primary irritation response to topical applications.


Conditional and Restricted Populations

Population Group Regulatory Status and Condition
Infants under 2 months Safety and efficacy are generally not established in this age group.
Children under 3 years Use is permitted only under medical supervision and limited to once daily.
Pregnant Women Not recommended during pregnancy, especially the first trimester (FDA Category C).
Breastfeeding Mothers Not recommended unless directed by a physician; avoid application to the nipple area.

Additionally, Crotamiton 10% must not be applied to acutely inflamed, raw, weeping, or broken skin surfaces.

Advertisements

What should I know about interactions with other medicines?

The official regulatory documents for Crotamiton 10% topical preparations define the interaction profile by the absence of documented interactions. The most authoritative government labeling explicitly states that Drug Interactions are None Known. This declaration forms the official regulatory basis for all interaction classifications and prescribing restrictions.

The regulatory documents confirm that no specific drug-drug interactions are currently known for the topical application of Crotamiton 10%. As a result, the prescribing information does not contain specific restrictions, prohibitions, or mandatory timing separation rules with other named medicinal products.

This status is consistently reflected across all major interaction categories defined by regulatory bodies:

Interaction Category Official Regulatory Status
Contraindicated Combinations None known.
Pharmacokinetic Interactions (Metabolic/Transporter) None known.
Pharmacodynamic Interactions None known.
Exposure-Modifying Substances None known.
Interactions with Food, Alcohol, or Supplements None documented.

The official profile does not list any medicinal products that would alter the exposure of Crotamiton, nor does it document any mechanistic basis for interactions, such as effects on drug-metabolizing enzymes or drug transporters. Similarly, the official documentation contains no statements related to interactions with food, alcohol, herbal products, or supplements. This entire regulatory structure related to co-administration is limited to the confirmation of no known interaction entities.

Advertisements

Mechanism of Action

Crotamiton acts primarily on arthropod neuronal membranes, demonstrating selective toxicity to the target organism. The core mechanism involves the direct interaction with voltage-gated sodium channels embedded in the nerve cell membrane. This binding event modifies the channel's kinetic properties, specifically inhibiting repolarization following excitation. The failure to restore the resting membrane potential leads to a sustained state of depolarization. This persistent electrical activity prevents the coordinated cycle of nerve firing necessary for muscle control, resulting in neuromuscular blockade in the target species. Separately, Crotamiton exhibits non-specific anti-inflammatory activity independent of its primary neuronal effect. This secondary pharmacodynamic mechanism involves modulating signaling pathways and reducing the release or action of certain mediators associated with inflammatory responses at the application site. The overall effect is a dual physiological modulation: disruption of targeted neural function and attenuation of localized inflammatory signaling.

Advertisements

Dosage and Administration Information

How to Use Crotamiton 10% — Official Administration Guidelines

The administration of Crotamiton 10% preparation is strictly topical (cutaneous) for its approved uses. The medication is generally available as a 10% concentration in cream or lotion form.

Standard Labeled Usage

For managing conditions requiring parasitic control, the official application regimen involves a two-day course. The preparation is massaged thoroughly over the entire body surface, extending from the chin to the soles of the feet, with careful attention to skin folds and creases. A second application is performed 24 hours after the first. For the lotion formulation, the container must be shaken well before use. To mitigate the risk of re-infestation, application under trimmed fingernails is part of the established procedure.

For providing symptomatic relief from pruritus (itching), the preparation is applied gently to the affected area until it is fully absorbed. This application may be repeated as needed, typically 2 to 3 times daily.

Procedural Constraints and Timing

Following the two-day regimen for parasitic control, a cleansing bath or shower is recommended 48 hours after the second application to remove residual medication. This defines the final endpoint of the treatment course. Additionally, clothing and bed linen used during the treatment should be changed and washed in a hot cycle to address potential contamination.

Specific constraints apply to pediatric use: for children under three years of age, the medication should be applied under medical supervision only, and application should not exceed once per day. No unique dosage adjustments are specified for older adults.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Crotamiton 10%


Evidence for Use in Scabies (Parasite Elimination)

The clinical evaluation of Crotamiton 10% for the context of scabies was studied using Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies evaluated two main outcomes: the Clinical Cure Rate (resolution of visible lesions) and the Parasitological Cure Rate (confirmed absence of live mites or eggs).

Research has mainly involved study populations of Adults and Older Children. Findings describe patterns related to Crotamiton 10% when evaluated in research exploring the parasitic infestation. However, the evidence base is considered limited, and evidence quality varies across studies. Some comparative trials have reported outcomes that were mixed or inconsistent, contributing to the finding that certainty remains low for drawing definitive conclusions about its comparative success rate.

Evidence for Use in Pruritus (Symptomatic Relief)

Crotamiton 10% was studied for its classification as an antipruritic, meaning it was evaluated in research exploring outcomes related to physical discomfort like intense itching. The focus was on patient-reported outcomes, tracking how symptoms evolved during the study period.

Studies monitored symptom intensity and how quickly itching changed. Historically, research has explored the use of Crotamiton 10% to address symptomatic discomfort in conditions characterized by fluctuating or episodic manifestations of severe itching. Findings describe patterns observed in the studies related to physical discomfort during the short term.

Research Gaps and Areas of Uncertainty

Evidence is limited by the fact that sample sizes were modest in many key trials. Furthermore, follow-up durations were limited, meaning little is known about long-term outcomes. A key gap relates to the difficulty in separating the two actions of the agent in a controlled setting. The available evidence provides context, but researchers note that findings were mixed regarding its comparative parasitic performance, and its independent anti-itch effect is not consistently documented across all available studies.

Key Studies & References Crotamiton 10% Drug Label - Information for the Patient (NIH DailyMed)

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Crotamiton 10% (FAQ)

Q: Does Crotamiton 10% treat the underlying skin condition or only help with the itching?

Official documents classify Crotamiton 10% as having a dual-action capability. It is categorized as both a scabicide, which is intended to eliminate the parasitic cause of certain skin conditions, and an antipruritic, which is intended to provide symptomatic relief from intense itching. This dual benefit addresses both the source of the problem and the discomfort.

Q: How quickly does Crotamiton 10% usually start to provide relief from itching?

Studies and official information indicate that Crotamiton 10% is used for symptomatic relief, focusing on patient-reported outcomes over the short term. While the exact onset time can vary for each individual and condition, its antipruritic classification suggests a primary function of helping to address discomfort after application.

Q: Can Crotamiton 10% be used to treat itching that is not caused by scabies?

Yes, the preparation is officially indicated for two separate uses. In addition to managing parasitic control, it is also indicated for the symptomatic relief of pruritus, or intense itching. This includes conditions where itching is present but is not caused by mites.

Q: What is the general guidance on using Crotamiton 10% during pregnancy?

According to the FDA, Crotamiton 10% is classified as Pregnancy Category C. Some international labels state that the use of this product is not generally recommended during pregnancy, particularly during the first trimester. Information regarding use during pregnancy requires consultation with a healthcare professional.

Q: Is Crotamiton 10% typically recommended for use in young children or infants?

Official labeling states that the use of Crotamiton 10% is generally not established for infants under 2 months of age. For children under 3 years old, use is restricted and permitted only under medical supervision. Official documents state that application should not exceed once per day for this age group.

Q: How long can a person expect to have itching after completing a course of Crotamiton 10% treatment for scabies?

It is commonly noted in official guidance that it is possible to continue experiencing some itching even after the full treatment course for scabies has been completed. This post-treatment itching may persist for up to two to four weeks.

Q: Is Crotamiton 10% available for purchase without a prescription in some regions?

Yes, regulatory status varies by country. According to official classification in some regions, Crotamiton 10% is designated as an Over-The-Counter (OTC) medicine. This means it is available for purchase without requiring a prescription for its approved uses.

Q: Does Crotamiton 10% have an expiry date, and does it become less effective over time?

Yes, like all pharmaceutical products, Crotamiton 10% has a determined shelf-life and a labeled expiration date. Official documents advise that the use of the product beyond its labeled expiration date is not recommended to support product stability and quality.

Q: How does the action of Crotamiton 10% differ when used for itching versus for mites?

The product has two distinct pharmacological mechanisms. The anti-mite effect involves disrupting the parasite’s neuronal function, leading to neuromuscular blockade. Separately, the anti-itching effect is due to a non-specific anti-inflammatory activity that helps modulate localized inflammatory signaling in the skin.

Q: What is the risk of systemic absorption of Crotamiton 10% through the skin?

Regulatory documents state that the exact extent of systemic absorption of crotamiton following topical application is not fully determined. However, some authoritative sources suggest that absorption is minimal. The classification as a localized treatment aligns with the suggested minimal absorption.

Q: What does the '10%' concentration indicate for Crotamiton's use?

The 10% concentration refers to the strength of the active ingredient, Crotamiton (100mg/ml), within the total product formulation. This is the standard, fixed concentration specified in regulatory documents for its labeled topical use as a scabicide and antipruritic.

Q: Are severe allergic reactions to Crotamiton 10% documented in official sources?

Official documentation recognizes the potential for allergic sensitivity reactions, including rare, more severe reactions like angioedema (swelling). Patient information describes signs that may indicate a severe allergic reaction, such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

Q: What symptoms should prompt stopping the use of Crotamiton 10%?

Official instructions state that treatment with Crotamiton 10% should be discontinued if the user experiences severe irritation or sensitization. This includes symptoms such as severe burning, stinging, or any persistent, worsening irritation on the skin.

Q: Are there specific warnings about accidental swallowing of Crotamiton 10%?

Yes, official patient information documents advise that accidental oral ingestion may be accompanied by a burning sensation in the mouth and irritation of the digestive tract. It may also lead to symptoms such as nausea, vomiting, and abdominal pain.

Q: Is Crotamiton 10% associated with any long-term skin changes or side effects after discontinuing use?

Regulatory reviews of the evidence base note that many key clinical trials had restricted follow-up durations. Due to these limitations, information regarding potential long-term skin changes or side effects that might occur after discontinuing use is not fully detailed in the official documents.

Q: Is Crotamiton 10% also used as a treatment for head lice or pubic lice?

The pharmacological class of Crotamiton includes Pediculicides, which are treatments for lice. Some international product labels explicitly state that Crotamiton 10% is indicated for the treatment of both scabies and pediculosis (lice infestation).

Q: What is the advised procedure if a dose of Crotamiton 10% is missed during treatment?

For the standard two-day treatment course, patient information advises that if the second application is missed, the full treatment may need to be started over. Official documents advise contacting a healthcare professional for specific guidance regarding any missed applications.

Q: Is a follow-up medical check generally recommended after using Crotamiton 10% for scabies?

A routine, mandatory follow-up medical check is not specified in the official administration guidelines. However, authoritative sources advise consulting a healthcare professional if itching or other symptoms persist 2 to 4 weeks after the treatment course is completed.

Q: Is there a distinction between the cream and lotion formulations of Crotamiton 10%?

Both the cream and lotion formulations contain the same concentration of the active ingredient, but they have different bases. The official documentation for the lotion requires that the container be shaken well before use for proper mixing. The lotion is generally recommended for applying to larger or hairier areas of the body.

Q: What is the general guidance on using Crotamiton 10% to prevent an infestation if a person was recently exposed?

Crotamiton 10% is officially indicated for the treatment and symptomatic relief of existing conditions. Its use as a prophylactic agent, meaning for prevention in a person who is uninfected but was recently exposed, is not listed in the product's approved indications.

Q: Does Crotamiton 10% contain any ingredients like benzyl alcohol that could be a concern for certain populations?

Yes, the inactive ingredients in some Crotamiton 10% formulations include excipients such as Benzyl Alcohol and Propylene Glycol. Authoritative warnings are associated with the use of Benzyl Alcohol in specific populations, particularly infants.

Q: Why is it advised to avoid applying Crotamiton 10% to the face?

Official documents restrict the product from use on the face due to its proximity to the eyes and mouth. The primary concern stated in regulatory documents is the risk of irritation if the product contacts the sensitive mucosal membranes in these areas.

Advertisements

How should Crotamiton 10% be stored and disposed of?

Crotamiton 10% must be stored according to specific environmental and container requirements documented in regulatory labeling to ensure product stability and safety.

Official Storage Requirements

  • Temperature: The product is required to be stored at Controlled Room Temperature, which is generally defined as 20^circ to 25 C (68^circ to 77 F), with permitted excursions for the lotion formulation up to 30 C. The cream formulation must not be stored above 25 C.
  • Protection: The medication must be protected from freezing and stored in a tight, light-resistant, and closed container.
  • Safety: The labeling mandates that Crotamiton 10% must be stored out of the reach of children.

Disposal Instructions

Applicators, such as a toothbrush used under the fingernails for application, must be wrapped in paper and thrown away immediately to prevent poisoning. Unused or expired medication should be disposed of by following specific label directions or by utilizing a drug take-back program. If neither is available, general regulatory guidance suggests mixing the product with an undesirable substance and sealing it before placing it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Crotamiton 10% found in:

A-Z Index: